The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...
As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...
Hespress on MSN17d
How early detection could save lives in Primary Hyperoxaluria Type 1Primary hyperoxaluria type 1 (PH1) is a metabolic stone disease that, if left undiagnosed, can have devastating consequences, including progressive kidney decline and end-stage kidney disease (ESKD).
Pharmaceutical Technology on MSN3d
Arbor to advance gene editing treatments with $73.9m fundingThe funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.
The YOLT-203 in-vivo gene editing therapy was developed to treat patients living with primary hyperoxaluria type 1 (PH1), a condition caused by a genetic deficiency in the liver enzyme alanine ...
Primary Hyperoxaluria (PH) is a rare autosomal recessive genetic disorder caused by enzyme deficiencies in hepatic oxalate metabolism, leading to excessive oxalate production and systemic oxalate ...
About Primary Hyperoxaluria Type 1 (PH1) PH1 is a potentially life-threatening progressive genetic disease characterized by the accumulation of oxalate in the kidney due to an enzyme deficiency in ...
Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...
Primary Hyperoxaluria (PH) is a rare autosomal recessive genetic disorder caused by enzyme deficiencies in hepatic oxalate metabolism, leading to excessive oxalate production and systemic oxalate ...
Tue, Feb 25, 2025, 3:15 AM 4 min read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback